Comparable stake leader
Medicxi IV LP
SEC ownership of RAPT Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001673772.
Disclosed value leader
GLAZER CAPITAL, LLC
Comparable rows
13/22
Latest evidence
03 Mar 2026
- Parsed ownership sources
-
13D/G and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Medicxi IV LP
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
13 of 22
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Medicxi IV LP
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
03 Mar 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001673772
- Issuer location
- South San Francisco, CA
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of RAPT Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Medicxi IV LP
Disclosed value leader
GLAZER CAPITAL, LLC
Comparable rows
13/22
Latest evidence
03 Mar 2026
13D/G
3/4/5
Lead comparable stake: 17%
9 rows are not safely comparable across share classes.
13D/G row: Medicxi IV LP
Showing 1-8 of 22 holder rows.
Quick read
Medicxi IV LP leads the comparable SEC ownership view at 17%.
13 of 22 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Medicxi IV LP's linked filing trail.
Comparable ownership
Top 5
Medicxi IV LP
17%
TCG Crossover GP II, LLC
10%
Redmile Group, LLC
9.9%
Foresite Capital Fund VI LP
9.3%
ForGrowth III PA B.V.
7.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-8 of 22 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Medicxi IV LP |
13D/G
Medicxi IV GP Limited
|
17%
|
$19,446,240
22,352,000 shares
|
$0 | 27 Dec 2024 |
| TCG Crossover GP II, LLC |
13D/G
|
10%
|
$11,478,006
13,193,110 shares
|
$0 | 27 Dec 2024 |
| Redmile Group, LLC |
13D/G
|
9.9%
|
$14,934,463
1,765,303 shares
|
$0 | 30 Jun 2025 |
| Foresite Capital Fund VI LP |
13D/G
Foresite Capital Fund VI, L.P.
|
9.3%
|
$10,875,000
12,500,000 shares
|
$0 | 23 Dec 2024 |
| ForGrowth III PA B.V. |
13D/G
|
7.4%
|
$47,291,008
1,833,333 shares
|
$0 | 23 Oct 2025 |
| GLAZER CAPITAL, LLC |
13D/G
|
5.4%
|
$50,334,004
1,486,094 shares
|
$0 | 02 Feb 2026 |
| COLUMN GROUP II, LP |
3/4/5
13D/G
Former 10% Owner · Peter Svennilson
|
4.9%
from 13D/G
|
$32,898,807
3,001,425 shares
mixed-class rows
|
— | 23 Dec 2024 |
| PERCEPTIVE ADVISORS LLC |
13D/G
|
4.5%
|
$5,115,600
5,880,000 shares
|
$0 | 31 Dec 2024 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 20 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-15 of 15 reporting-owner rows connected to RAPT Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
15
Largest Forms 3/4/5 holder
COLUMN GROUP II, LP
Net 12M change
$0
Latest report
03 Mar 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| COLUMN GROUP II, LP | Former 10% Owner | $32,898,807 | Mixed | 23 Dec 2024 | ||
| Wendye Robbins | Director | $329,096 | Mixed | 31 Mar 2025 | ||
| William Jl Rieflin | Director | $276,594 | Mixed | 22 May 2024 | ||
| Mary Ann Gray | Director | $65,003 | Mixed | 03 Mar 2026 | ||
| Peter Svennilson | Director, 10%+ Owner | $56,850 | Mixed | 28 May 2021 | ||
| Lori Lyons-Williams | Director | $0 | Mixed | 03 Mar 2026 | ||
| Brian Russell Wong | PRESIDENT AND CEO, Director | $0 | Mixed | 03 Mar 2026 | ||
| Rodney Kb Young | Chief Financial Officer | $0 | Mixed | 03 Mar 2026 | ||
| Michael F. Giordano | Director | $0 | Mixed | 03 Mar 2026 | ||
| Scott Braunstein | Director | $0 | Mixed | 03 Mar 2026 | ||
| Linda Kozick | Director | $0 | Mixed | 03 Mar 2026 | ||
| Dirk G. Brockstedt | Chief Scientific Officer | $0 | Mixed | 03 Mar 2026 | ||
| Ashley L. Dombkowski | Director | $0 | Mixed | 03 Mar 2026 | ||
| William Ho | Chief Medical Officer | Mixed | 20 Jun 2025 | |||
| Medicxi Ventures Management (Jersey) Ltd | 10%+ Owner | Mixed | 27 Dec 2024 |
Recent insider transactions for RAPT Therapeutics, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Lori Lyons-Williams | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,956 | 0 | 03 Mar 2026 | Direct | ||
| Lori Lyons-Williams | RAPT | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -42,284 | 0 | 03 Mar 2026 | Direct | ||
| Mary Ann Gray | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,956 | 0 | 03 Mar 2026 | Direct | ||
| Mary Ann Gray | RAPT | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -54,902 | 0 | 03 Mar 2026 | Direct | ||
| Michael F. Giordano | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,956 | 0 | 03 Mar 2026 | Direct | ||
| Michael F. Giordano | RAPT | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -43,372 | 0 | 03 Mar 2026 | Direct | ||
| Ashley L. Dombkowski | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,956 | 0 | 03 Mar 2026 | Direct | ||
| Ashley L. Dombkowski | RAPT | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -25,000 | 0 | 03 Mar 2026 | Direct | ||
| Rodney Kb Young | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -3,304 | 0 | 03 Mar 2026 | Direct | ||
| Rodney Kb Young | RAPT | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -202,399 | 0 | 03 Mar 2026 | Direct | ||
| Dirk G. Brockstedt | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,648 | 0 | 03 Mar 2026 | Direct | ||
| Dirk G. Brockstedt | RAPT | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -160,094 | 0 | 03 Mar 2026 | Direct | ||
| Brian Russell Wong | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -64,102 | 0 | 03 Mar 2026 | Direct | ||
| Brian Russell Wong | RAPT | Employee Stock Option (right to buy) | Disposed to Issuer | -100% | -763,251 | 0 | 03 Mar 2026 | Direct | ||
| Linda Kozick | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,956 | 0 | 03 Mar 2026 | Direct | ||
| Linda Kozick | RAPT | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -46,806 | 0 | 03 Mar 2026 | Direct | ||
| Scott Braunstein | RAPT | Common Stock | Disposition pursuant to a tender of shares in a change of control transaction | -100% | -4,956 | 0 | 03 Mar 2026 | Direct | ||
| Scott Braunstein | RAPT | Director Stock Option (right to buy) | Disposed to Issuer | -100% | -25,000 | 0 | 03 Mar 2026 | Direct | ||
| Linda Kozick | RAPT | Common Stock | Award | 4,956 | 4,956 | 30 Jan 2026 | Direct | |||
| Michael F. Giordano | RAPT | Common Stock | Award | 4,956 | 4,956 | 30 Jan 2026 | Direct | |||
| Lori Lyons-Williams | RAPT | Common Stock | Award | 4,956 | 4,956 | 30 Jan 2026 | Direct | |||
| Scott Braunstein | RAPT | Common Stock | Award | 4,956 | 4,956 | 30 Jan 2026 | Direct | |||
| Ashley L. Dombkowski | RAPT | Common Stock | Award | 4,956 | 4,956 | 30 Jan 2026 | Direct | |||
| Mary Ann Gray | RAPT | Common Stock | Award | 4,956 | 4,956 | 30 Jan 2026 | Direct |
* marks a reported price that did not pass the local price check.